Clinical trials: Myasthenia Gravis (MG)

Myasthenia Gravis (MG)

Ripertamab for the Treatment of Myasthenia Gravis

• Not yet recruiting
• Age: 18 to 75 years
• Phase 1/2
• Injection or infusion

The goal of this clinical trial is to learn if ripertamab works to treat myasthenia gravis. It will also learn about the safety of ripertamab.

Trial name

RIPERT-MG (NCT07372807)

Testing

ripertamab

Volunteers

20 people

Sponsor

Zhongming Qiu